Development of sarcoidosis during etanercept therapy.
González-López
Marcos A
MA
Hospital Universitario Marqués de Valdecilla, Universidad de Cantabria, Santander, Spain.
Blanco
Ricardo
R
González-Vela
M Carmen
MC
Fernández-Llaca
Héctor
H
Rodríguez-Valverde
Vicente
V
D000368:Aged; D018501:Antirheumatic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D016207:Cytokines / Q000502:physiology; D000068800:Etanercept; D006099:Granuloma / Q000209:etiology / Q000503:physiopathology; D006801:Humans; D007074:Immunoglobulin G / Q000009:adverse effects* / Q000627:therapeutic use; D008297:Male; D009363:Neoplasm Proteins / Q000009:adverse effects / Q000627:therapeutic use; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use; D047889:Receptors, Tumor Necrosis Factor, Type II / Q000627:therapeutic use; D012507:Sarcoidosis / Q000139:chemically induced* / Q000503:physiopathology; D013167:Spondylitis, Ankylosing / Q000188:drug therapy / Q000503:physiopathology; D053319:Tumor Necrosis Factor Decoy Receptors
D018501:Antirheumatic Agents; D016207:Cytokines; D007074:Immunoglobulin G; D009363:Neoplasm Proteins; D018124:Receptors, Tumor Necrosis Factor; D047889:Receptors, Tumor Necrosis Factor, Type II; D053319:Tumor Necrosis Factor Decoy Receptors; D000068800:Etanercept